EditorialReferring to the article published on pp. 613–622 of this issueStereotactic Ablative Body Radiotherapy: An Emerging Weapon in the Treatment Armamentarium for Renal Cell Carcinoma or a Potential Avenue for Overtreatment?
Referring to the article published on pp. 613–622 of this issue
References (15)
- et al.
Epidemiology of renal cell carcinoma
Eur Urol
(2019) - et al.
The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma
Eur Urol
(2022) - et al.
Active surveillance for localized renal masses: tumor growth, delayed intervention rates, and >5-yr clinical outcomes
Eur Urol
(2018) - et al.
Growth kinetics and short-term outcomes of cT1b and cT2 renal masses under active surveillance
J Urol
(2014) - et al.
Stereotactic ablative radiation therapy for renal cell carcinoma with inferior vena cava tumor thrombus
Urol Oncol
(2022) - et al.
Neoadjuvant SABR for renal cell carcinoma inferior vena cava tumor thrombus—safety lead-in results of a phase 2 trial
Int J Radiat Oncol Biol Phys
(2021) - et al.
Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial
Lancet Oncol
(2021)
There are more references available in the full text version of this article.
Cited by (0)
© 2022 Published by Elsevier B.V. on behalf of European Association of Urology.